Reuniting With the Affable Mr. Greg Halpern, 19 Years Later…

A Potential Christmas Present Arrives in our lap Early, From the Inventor of Crowdfunding and Winner of Incubator of The Year in...

News and Charts on Four Small Cap Telehealth and Remote Health Monitoring Plays.

After Losing $33 Billion in Value, Teladoc Health Snags an Upgrade. With chances building...
VYRE Network

Report: VYRE Network (CAPV).

Update Report: Our First Internet Play in Ages, and It’s a Doozy. Reporting from the Great City...

Dalrada (DFCO). Our 11th and Latest Ten Bagger.

We've actually had many more than 11 ten-baggers, as we report on companies which aren't clients. This is our 11th client we...

The Race to Develop Therapeutics for COVID. The Small Caps Fight for a Treatment...

The Second Wave: Biopharma Players Race to Develop Therapeutics for COVID-19 (BioSPace) December 21. Revive Therapeutics (RVTTF), RedHill BioPharma...

Revive Therapeutics (RVVTF) Provides Update of Psilocybin Pharmaceutical Programs

IRB approval to initiate Phase 2 study for methamphetamine abuse disordersAdvancing psilocybin oral thin film, microneedle patch and biosynthesis programs

Revive Therapeutics Updates, on Phase III Clinical Trial!

Michael Frank, CEO of the Company commented, "We are now in the final stages in our Phase 3 study.."
Revive Therapeutics

Revive Therapeutics (RVVTF, RVV): Updates and News Archive.

Recent Headlines (See FDA Filing Submission at Bottom) LIVE QUOTE

Revive Therapeutics (RVVTF) Regulatory Update Archive.

April 12th, 2022 update. Discusses potentially halting the Study early due to positive efficacy based on other clinical outcomes evaluated such as...

Report: First Vaccines, then Antivirals. Will the Anti-Inflammatory Be the Next Success Story in...

New Report on Revive Therapeutics (RVVTF, RVV). Ushering in Advances in Anti-Inflammatory and Antioxidant Drugs, as a Tool Against Covid.

Latest article

Ardelyx (ARDX) Reports First Quarter 2024 Showing $204 Million in Cash!

When we added Ardelyx (ARDX) to the Watch List in November of 2022, the market cap near $80 million. Now it's...

GeoVax to Provide Corporate Update on Tuesday May 14, 2024.

Still our favorite biotech microcap, still our favorite management team, and our favorite risk to reward idea with a $4 million market...

NovaVax (NVAX) Roars Higher, Gaining 225% a $1.2 Billion Increase, at the Blink of...

Sanofi (SNY) Announces Partnership - $500 Million Upfront, plus $700 million in Milestones with NovaVax (NVAX). And some investors say Covid is...